A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

O’Donnell, Elizabeth; P. Laubach, Jacob; J. Yee, Andrew; Ann Huff, Carol; G. Basile, Frank; M. Wade, Philip; E. Paba‐Prada, Claudia; M. Ghobrial, Irene; Schlossman, Robert; Couture, Nicole; Doherty, Lauren; Lyons, Hannah; English, Caroline; C. Munshi, Nikhil; C. Anderson, Kenneth; G. Richardson, Paul; Raje, Noopur

doi:10.1182/blood.v124.21.3454.3454

Public

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Published in Blood • Dec 6, 2014

Authors:

Elizabeth O’Donnell

Jacob P. Laubach

Andrew J. Yee

Abstract

Abstract Background: Multiple myeloma (MM) is primarily a disease of older adults with a median age at diagnosis of 66 years. Despite significant improvements in patient outcomes, there is a lag in survival in older transplant-ineligible patients compared to their younger counterparts. Traditionally...

Subject

Medicine

Lenalidomide

Multiple myeloma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!